Hypersensitivity reactions to the quadrivalent HPV vaccine are rare

Dec 03, 2008

Hypersensitivity reactions to the quadrivalent HPV vaccine (4vHPV, Gardasil) are uncommon and most schoolgirls can tolerate subsequent doses, finds the first evaluation of the quadrivalent HPV vaccine published on bmj.com today.

In Australia, from April 2007, all females aged 12󈞆 years received the 4vHPV vaccine as part of a national secondary school immunisation programme. Some components of the vaccine such as aluminium salts and yeast have previously been associated with hypersensitivity reactions. Reports of some adverse events followed the school vaccination programme.

Dr Sharon Choo and colleagues from Australia describe the results of clinical evaluation, skin tests, and vaccine challenge in 25 schoolgirls with suspected hypersensitivity to 4vHPV after more than 380,000 vaccine doses were administered in schools in Victoria and South Australia.

Thirty five schoolgirls with suspected hypersensitivity reactions including urticaria (hives), generalised rash, angioedema (swelling of subcutaneous tissues) and anaphylaxis were reported to specialised immunisation services and 25 agreed to be referred to paediatric allergy centres for further evaluation.

A detailed account of the reactions was noted including previous doses of the vaccine, time and severity of reaction, and previous clinical history. Skin prick tests of the quadrivalent and bivalent HPV vaccines were carried out, and vaccine challenges were administered intramuscularly. The school-girls were followed-up by telephone one week after the subsequent dose and any adverse events were recorded.

The researchers report that 19 girls had skin testing of the quadrivalent vaccine and all were negative. Seventeen of the 18 girls subsequently challenged with the quadrivalent vaccine tolerated further doses. One reported limited urticaria (hives) four hours after the vaccine was given.

Only three of the 25 evaluated schoolgirls had probable hypersensitivity to the quadrivalent vaccine, and the authors conclude that true hypersensitivity is uncommon. They point out that suspected hypersensitivity reactions such as hives are often "idiosyncratic" and do not increase the risk of adverse reactions in subsequent vaccinations.

The authors recommend that girls with suspected hypersensitivity to the quadrivalent vaccine should be evaluated before receiving more doses, and call for research into the mechanisms of hypersensitivity to the vaccine.

Source: British Medical Journal

Explore further: FDA approves hard-to-abuse narcotic painkiller

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Determine patient preferences by means of conjoint analysis

1 hour ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0